AmCad BioMed Corporation (TPEX:4188)
Taiwan · Delayed Price · Currency is TWD 11.15
-0.10 (-0.89%)
May 29, 2026, 1:30 PM CST
AmCad BioMed Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 30.04 | 30.44 | 53.11 | 65.26 | 61.63 | 85.79 | |
Revenue Growth (YoY) | -42.01% | -42.69% | -18.62% | 5.88% | -28.16% | 34.17% |
Cost of Revenue | 19.31 | 20.41 | 20.17 | 24.23 | 23.58 | 25.13 |
Gross Profit | 10.74 | 10.02 | 32.93 | 41.02 | 38.05 | 60.67 |
Selling, General & Admin | 49.42 | 50.87 | 53.82 | 50.89 | 48.39 | 46.59 |
Research & Development | 46.28 | 47.11 | 43.78 | 44.12 | 54 | 50.95 |
Operating Expenses | 95.7 | 97.98 | 97.6 | 95.01 | 102.34 | 97.44 |
Operating Income | -84.96 | -87.96 | -64.66 | -53.99 | -64.3 | -36.77 |
Interest Expense | -0.11 | -0.09 | -0.18 | -0.12 | -0.12 | -0.14 |
Interest & Investment Income | 9.33 | 9.3 | 6.18 | 4.71 | 4.72 | 3.73 |
Currency Exchange Gain (Loss) | -0.23 | -0.23 | 0.02 | 0.09 | 1.7 | 1.98 |
Other Non Operating Income (Expenses) | 7.35 | 7.31 | 5.93 | 6.32 | 3.66 | 4.38 |
EBT Excluding Unusual Items | -68.63 | -71.67 | -52.72 | -42.98 | -54.35 | -26.82 |
Gain (Loss) on Sale of Investments | 0.46 | 0.46 | 0.03 | 0 | 0.02 | 0 |
Gain (Loss) on Sale of Assets | -0.22 | -0.22 | -0.19 | -0.17 | -0.01 | -0.08 |
Other Unusual Items | 0.02 | 0.02 | - | 0 | - | - |
Pretax Income | -68.36 | -71.4 | -52.88 | -43.15 | -54.34 | -26.89 |
Income Tax Expense | -0.02 | -0.02 | - | - | - | - |
Earnings From Continuing Operations | -68.35 | -71.39 | -52.88 | -43.15 | -54.34 | -26.89 |
Minority Interest in Earnings | 14.69 | 15.67 | 2.3 | -2.17 | 0.86 | 1.35 |
Net Income | -53.66 | -55.72 | -50.58 | -45.31 | -53.49 | -25.54 |
Net Income to Common | -53.66 | -55.72 | -50.58 | -45.31 | -53.49 | -25.54 |
Shares Outstanding (Basic) | 64 | 63 | 58 | 53 | 53 | 53 |
Shares Outstanding (Diluted) | 64 | 63 | 58 | 53 | 53 | 53 |
Shares Change (YoY) | 6.46% | 9.75% | 8.42% | 0.01% | - | 0.09% |
EPS (Basic) | -0.84 | -0.88 | -0.88 | -0.85 | -1.01 | -0.48 |
EPS (Diluted) | -0.84 | -0.88 | -0.88 | -0.85 | -1.01 | -0.48 |
Free Cash Flow | -47.11 | -47.44 | -54.57 | -41.89 | -34.81 | -41.3 |
Free Cash Flow Per Share | -0.74 | -0.75 | -0.95 | -0.79 | -0.65 | -0.78 |
Gross Margin | 35.73% | 32.93% | 62.02% | 62.87% | 61.73% | 70.71% |
Operating Margin | -282.80% | -288.97% | -121.77% | -82.73% | -104.33% | -42.86% |
Profit Margin | -178.59% | -183.06% | -95.24% | -69.44% | -86.79% | -29.78% |
Free Cash Flow Margin | -156.80% | -155.85% | -102.76% | -64.20% | -56.48% | -48.14% |
EBITDA | -74.38 | -77.48 | -51.94 | -41.26 | -51.48 | -23.46 |
EBITDA Margin | -247.57% | -254.57% | -97.81% | -63.22% | -83.52% | -27.35% |
D&A For EBITDA | 10.58 | 10.47 | 12.72 | 12.73 | 12.82 | 13.31 |
EBIT | -84.96 | -87.96 | -64.66 | -53.99 | -64.3 | -36.77 |
EBIT Margin | -282.80% | -288.97% | -121.77% | -82.73% | -104.33% | -42.86% |